TW200305395A - Organic compounds - Google Patents
Organic compounds Download PDFInfo
- Publication number
- TW200305395A TW200305395A TW092105495A TW92105495A TW200305395A TW 200305395 A TW200305395 A TW 200305395A TW 092105495 A TW092105495 A TW 092105495A TW 92105495 A TW92105495 A TW 92105495A TW 200305395 A TW200305395 A TW 200305395A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- alkyl
- substituted
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0206218A GB0206218D0 (en) | 2002-03-15 | 2002-03-15 | Organic compounds |
| GB0229627A GB0229627D0 (en) | 2002-12-19 | 2002-12-19 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200305395A true TW200305395A (en) | 2003-11-01 |
Family
ID=28043401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092105495A TW200305395A (en) | 2002-03-15 | 2003-03-13 | Organic compounds |
| TW096115427A TW200800167A (en) | 2002-03-15 | 2003-03-13 | Organic compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096115427A TW200800167A (en) | 2002-03-15 | 2003-03-13 | Organic compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7288537B2 (enExample) |
| EP (1) | EP1487435A1 (enExample) |
| JP (2) | JP4332433B2 (enExample) |
| KR (1) | KR100706270B1 (enExample) |
| CN (1) | CN1638761A (enExample) |
| AR (1) | AR041786A1 (enExample) |
| AU (1) | AU2003227072B2 (enExample) |
| BR (1) | BR0308419A (enExample) |
| CA (1) | CA2479266A1 (enExample) |
| CO (1) | CO5611125A2 (enExample) |
| IL (1) | IL164016A0 (enExample) |
| MX (1) | MXPA04009057A (enExample) |
| NO (1) | NO20044373L (enExample) |
| NZ (1) | NZ535082A (enExample) |
| PL (1) | PL371055A1 (enExample) |
| RU (1) | RU2314292C2 (enExample) |
| TW (2) | TW200305395A (enExample) |
| WO (1) | WO2003077907A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| US20070021404A1 (en) * | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2534550A1 (en) * | 2003-09-15 | 2005-03-24 | Novartis Ag | 1, 3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases |
| GB0402101D0 (en) * | 2004-01-30 | 2004-03-03 | Novartis Ag | Organic compounds |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| CA2584342C (en) | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0720389D0 (en) * | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) * | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| BR112013017302B1 (pt) | 2011-01-07 | 2021-12-07 | Novartis Ag | Composição farmacêutica em fase sólida |
| EP3613435A1 (en) | 2015-01-28 | 2020-02-26 | Universite De Bordeaux | Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease |
| IL276295B2 (en) | 2018-01-26 | 2024-02-01 | Rapt Therapeutics Inc | Modulators of chemokine receptors and their uses |
| CN110498750B (zh) * | 2019-09-02 | 2021-10-15 | 南通大学 | 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| US12221463B2 (en) | 2020-08-07 | 2025-02-11 | The Board Of Regents Of The University Of Oklahoma | Method of promoting wound healing by inhibiting CCR3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2093456B (en) | 1980-10-08 | 1984-12-05 | Robins Co Inc A H | 1-r1-3-phenozyazetidines |
| US5095014A (en) * | 1990-12-07 | 1992-03-10 | A. H. Robins Company, Incorporated | 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity |
| DE4335718A1 (de) * | 1993-10-20 | 1995-04-27 | Merck Patent Gmbh | Cyclische Aminderivate |
| WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| GB0019006D0 (en) * | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| GB0117387D0 (en) * | 2001-07-17 | 2001-09-05 | Novartis Ag | Organic compounds |
-
2003
- 2003-03-13 TW TW092105495A patent/TW200305395A/zh unknown
- 2003-03-13 AR ARP030100876A patent/AR041786A1/es not_active Application Discontinuation
- 2003-03-13 TW TW096115427A patent/TW200800167A/zh unknown
- 2003-03-14 AU AU2003227072A patent/AU2003227072B2/en not_active Ceased
- 2003-03-14 IL IL16401603A patent/IL164016A0/xx unknown
- 2003-03-14 RU RU2004130487/04A patent/RU2314292C2/ru not_active IP Right Cessation
- 2003-03-14 US US10/507,139 patent/US7288537B2/en not_active Expired - Fee Related
- 2003-03-14 CN CNA038056488A patent/CN1638761A/zh active Pending
- 2003-03-14 JP JP2003575960A patent/JP4332433B2/ja not_active Expired - Fee Related
- 2003-03-14 WO PCT/EP2003/002715 patent/WO2003077907A1/en not_active Ceased
- 2003-03-14 KR KR1020047013800A patent/KR100706270B1/ko not_active Expired - Fee Related
- 2003-03-14 PL PL03371055A patent/PL371055A1/xx not_active Application Discontinuation
- 2003-03-14 BR BR0308419-1A patent/BR0308419A/pt not_active IP Right Cessation
- 2003-03-14 EP EP03744367A patent/EP1487435A1/en not_active Withdrawn
- 2003-03-14 CA CA002479266A patent/CA2479266A1/en not_active Abandoned
- 2003-03-14 MX MXPA04009057A patent/MXPA04009057A/es active IP Right Grant
- 2003-03-14 NZ NZ535082A patent/NZ535082A/en unknown
-
2004
- 2004-09-14 CO CO04091228A patent/CO5611125A2/es not_active Application Discontinuation
- 2004-10-14 NO NO20044373A patent/NO20044373L/no not_active Application Discontinuation
-
2008
- 2008-11-27 JP JP2008302924A patent/JP2009102325A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1638761A (zh) | 2005-07-13 |
| JP4332433B2 (ja) | 2009-09-16 |
| US20050222118A1 (en) | 2005-10-06 |
| BR0308419A (pt) | 2005-01-18 |
| AU2003227072B2 (en) | 2006-08-10 |
| EP1487435A1 (en) | 2004-12-22 |
| RU2314292C2 (ru) | 2008-01-10 |
| NZ535082A (en) | 2006-08-31 |
| JP2009102325A (ja) | 2009-05-14 |
| IL164016A0 (en) | 2005-12-18 |
| CA2479266A1 (en) | 2003-09-25 |
| CO5611125A2 (es) | 2006-02-28 |
| JP2005526773A (ja) | 2005-09-08 |
| PL371055A1 (en) | 2005-06-13 |
| KR20040091690A (ko) | 2004-10-28 |
| KR100706270B1 (ko) | 2007-04-11 |
| TW200800167A (en) | 2008-01-01 |
| RU2004130487A (ru) | 2005-07-10 |
| US7288537B2 (en) | 2007-10-30 |
| AU2003227072A1 (en) | 2003-09-29 |
| AR041786A1 (es) | 2005-06-01 |
| NO20044373L (no) | 2004-10-14 |
| WO2003077907A1 (en) | 2003-09-25 |
| MXPA04009057A (es) | 2005-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200305395A (en) | Organic compounds | |
| KR101235962B1 (ko) | 질환의 치료에 유용한 트라이아졸 유도체 | |
| TWI227231B (en) | 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3 | |
| CN102164920B (zh) | 烷基噻唑氨基甲酸酯衍生物、其制备方法和其作为faah酶抑制剂的用途 | |
| JP2022521825A (ja) | アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法 | |
| CN103351367B (zh) | 5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的盐酸盐 | |
| CA2686517A1 (en) | Azetidine derivatives and their use as prostaglandin e2 antagonists | |
| JP4221447B1 (ja) | ムスカリン様受容体アンタゴニストとしてのカルボキサミド誘導体 | |
| CN102844301B (zh) | 新苯甲酰胺衍生物 | |
| WO2005113499A1 (ja) | インドール化合物 | |
| EP2066626B1 (en) | Azetidine derivatives as muscarinic receptor antagonists | |
| US8278343B2 (en) | Pyrrolidines | |
| ES2286664T3 (es) | Derivados de azetidina 1,3-disustituida para ser utilizados como antagonistas del receptor ccr en el tratamiento de enfermedades inflamatorias y alergicas. | |
| CA2700936A1 (en) | Production method for pyrazol-3-yl-benzamide derivative | |
| EP2222665A1 (en) | Azetidines as ep2 antagonists | |
| JP4199539B2 (ja) | Ｃｃｒ−３受容体アンタゴニストとしてのｎ−（４−アリールオキシピペリジン−１−イルアルキル）桂皮酸アミド | |
| JP2007137810A (ja) | インドール化合物を含有する医薬 | |
| RU2278856C2 (ru) | Производные пиперидина и способ их получения |